Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-16-0313
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

PUB047 Efficacy of EGFR-TKI for Lung Adenosquamous Cell Carcinoma Harboring EGFR Mutation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

P063 STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-002 Concurrent EGFR T790M Secondary Mutation and EMT in a Lung Adenocarcinoma Patient With EGFR TKI Drug Resistance

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Responses to Crizotinib Can Occur in C-Met Overexpressing Nonsmall Cell Lung Cancer After Developing EGFR-TKI Resistance

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2018English

P3.01-60 a Novel MET D1246H Mutation After Progression of EGFR-TKI/MET Inhibitor Combined Therapy in a NSCLC Patient With Acquired MET Amplification

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.13-12 a Lung Adenocarcinoma With Concomitant EGFR and De Novo MET Amplification Response Well to Combination of TKI and Bevacizumab

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Post-Progression Survival After EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations

PLoS ONE
Multidisciplinary
2015English

P3.01-24 the Importance to Switch From EGFR-TKI to Cytotoxic Chemotherapy for EGFR Mutation-Positive Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

Lung Cancer Management
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy